Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Kallikrein 10 Antibodies:
anti-Rat (Rattus) Kallikrein 10 Antibodies:
anti-Human Kallikrein 10 Antibodies:
Go to our pre-filtered search.
Human Monoclonal Kallikrein 10 Primary Antibody for WB - ABIN968673
Goyal, Smith, Cowan, Wazer, Lee, Band: The role for NES1 serine protease as a novel tumor suppressor. in Cancer research 1998
Show all 3 Pubmed References
Human Polyclonal Kallikrein 10 Primary Antibody for IF (p), IHC (p) - ABIN741630
Wang, Schwab, Fan, Seagroves, Buolamwini: Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. in Cancer prevention research (Philadelphia, Pa.) 2013
Show all 2 Pubmed References
identification and molecular cloning of eight novel transcripts of the human KLK10 gene using 3' rapid amplification of cDNA ends (3' RACE) and next-generation sequencing (NGS), as well as their expression analysis in a wide panel of cell lines, originating from several distinct cancerous and normal tissues
Data suggest that mature KLK9 (kallikrein 9 (show KLK9 Antibodies)) is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at P1 cleavage position; substrate specificity of KLK9 (show KLK9 Antibodies) appears to extend to KLK10 and midkine (show MDK Antibodies); enzyme activity is enhanced by Mg2 (show MUC7 Antibodies)+ and Ca2 (show CA2 Antibodies)+, but is reversibly attenuated by Zn2+; KLK9 (show KLK9 Antibodies) is inhibited in vitro by many naturally occurring or synthetic protease inhibitors.
KLK10 potentially plays a crucial role in esophageal cancer cell growth.
KLK10 may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 (show PCSK1 Antibodies) cells.
treated and untreated prolactin (show PRL Antibodies)-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10
Immunoexpression of KLK10 in the ACTH (show POMC Antibodies)-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of non-tumorous pituitaries.
Data indicate that elevated expression of microRNA-375 in head and neck squamous cell carcinoma (HNSCC) cells significantly reduces kallikrein 6 (KLK6 (show KLK6 Antibodies)), kallikrein 10 (KLK10), and matrix metalloproteinase 9 (MMP9 (show MMP9 Antibodies)) messenger RNA expression.
is the first correlation of oral squamous cell carcinoma with KLK10 rs3745535G>T polymorphisms
KLK6 (show KLK1 Antibodies) and KLK10 may be useful markers and potential therapeutic targets in gastroesophageal junction tumors
This study assessed the prognostic utility of human tissue kallikrein (show KLK1 Antibodies)-like peptidases 6 and 10 (KLK6 (show KLK1 Antibodies) and KLK10) and correlated their expression with histopathological and clinical parameters in gastric cancer.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its encoded protein is secreted and may play a role in suppression of tumorigenesis in breast and prostate cancers. Alternate splicing of this gene results in multiple transcript variants encoding the same protein.
kallikrein-related peptidase 10
, kallikrein 10
, breast normal epithelial cell associated serine protease
, normal epithelial cell-specific 1
, protease serine-like 1
, protease, serine-like, 1